Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index; 26 of the 48 sources its claims cite were checked for support.
Abstract
Candida albicans is the leading fungal pathogen of humans, causing life-threatening disease in immunocompromised individuals. Treatment of candidiasis is hampered by the limited number of antifungal drugs whose efficacy is compromised by host toxicity, fungistatic activity, and the emergence of drug resistance. We previously established that the molecular chaperone Hsp90, which regulates the form and function of diverse client proteins, potentiates resistance to the azoles in C. albicans and in the model yeast Saccharomyces cerevisiae. Genetic studies in S. cerevisiae revealed that Hsp90's role in azole resistance is to enable crucial cellular responses to the membrane stress exerted by azoles via the client protein calcineurin. Here, we demonstrate that Hsp90 governs cellular circuitry required for resistance to the only new class of antifungals to reach the clinic in decades, the echinocandins, which inhibit biosynthesis of a critical component of the fungal cell wall. Pharmacological or genetic impairment of Hsp90 function reduced tolerance of C. albicans laboratory strains and resistance of clinical isolates to the echinocandins and created a fungicidal combination. Compromising calcineurin function phenocopied compromising Hsp90 function. We established that calcineurin is an Hsp90 client protein in C. albicans: reciprocal co-immunoprecipitation validated physical interaction; Hsp90 inhibition blocked calcineurin activation; and calcineurin levels were depleted upon genetic reduction of Hsp90. The downstream effector of calcineurin, Crz1, played a partial role in mediating calcineurin-dependent stress responses activated by echinocandins. Hsp90's role in echinocandin resistance has therapeutic potential given that genetic compromise of C. albicans HSP90 expression enhanced the efficacy of an echinocandin in a murine model of disseminated candidiasis. Our results identify the first Hsp90 client protein in C. albicans, establish an entirely new role for Hsp90 in mediating resistance to echinocandins, and demonstrate that targeting Hsp90 provides a promising therapeutic strategy for the treatment of life-threatening fungal disease.
Overview
CoChat Summary
## TL;DR
Hsp90 is required for *Candida albicans* tolerance to echinocandins, and this effect depends largely on calcineurin. Genetic or pharmacological impairment of Hsp90 or calcineurin made micafungin more effective in vitro and in a murine disseminated infection model.
## Key findings
- In antifungal susceptibility and spotting assays, inhibiting Hsp90 with geldanamycin (GdA) or radicicol (RAD) “dramatically enhanced” sensitivity to micafungin (MF) in two strains, and comparable effects were seen with caspofungin (CS).
- Compromising Hsp90 function made the tetO-HSP90/hsp90Δ strain hypersensitive to MF even without tetracycline, and restoring a wild-type HSP90 allele complemented both the reduced growth rate and MF hypersensitivity.
- Inhibiting calcineurin with cyclosporin A (CsA) or FK506 abolished MF tolerance; deleting CNA1 or CNB1 also abrogated MF tolerance, while CRZ1 deletion caused only a partial loss of MF tolerance.
- In the murine model, mice infected with the tetO-HSP90/hsp90Δ strain had significantly reduced kidney fungal burden than mice infected with wild-type HSP90 strain (P<0.05), and MF further reduced fungal burden in the tetO-HSP90/hsp90Δ group (P<0.001).
## Methods
- The study combined pharmacological inhibition (GdA, RAD, CsA, FK506) and genetic perturbation (HSP90, CNA1, CNB1, CRZ1 mutants; tetO-HSP90/hsp90Δ; MAL2p-HSP90/hsp90Δ) in *C. albicans* and *S. cerevisiae*.
- Antifungal tolerance was measured using modified broth microdilution MIC assays, checkerboard synergy assays, and spotting assays on liquid and solid media with MF and CS.
- Mechanistic tests included β-galactosidase reporter assays for calcineurin activation, co-immunoprecipitation of tagged Hsp90 and Cna1, immunoblotting for protein levels, and a tail-vein murine disseminated candidiasis model with kidney CFU readout.
## Limitations
- The paper explicitly notes that the basis for the different responses with micafungin and caspofungin on solid medium is unclear, and the response with anidulafungin “remains to be determined.”
- The authors state that synergy between Hsp90/calcineurin inhibitors and MF was not observed for all echinocandin-resistant clinical isolates tested; of 14 FKS1 mutants, synergy was observed for 8.
- Evidence on cidality was limited by MF-induced clumping, which made CFU counts inaccurate in the echinocandin killing assay; this is stated in the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
19 Valid · 3 Not valid · 19 Not checked · 75 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“This antibody also demonstrated synergy with the echinocandin caspofungin in a murine model [53].”
§ Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin > Discussion
What the sources say
- Supportedcites [53] S Hodgetts, 2008, Efungumab and caspofungin: pre-clinical data supporting synergy., J Antimicrob Chemother source
The Introduction identifies efungumab as a human recombinant antibody fragment against Hsp90. The Abstract reports a statistically significant improvement with efungumab plus caspofungin in mice infected with fluconazole-resistant C. albicans, supporting the claimed synergy in a murine model. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Current Hsp90 inhibitors that are well-tolerated in humans as anti-cancer agents exhibit toxicity in the mouse model in the context of an acute fungal infection [22].”
§ Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin > Discussion
What the sources say
- Supportedcites [22] LE Cowen, 2009, Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease., Proc Natl Acad Sci U S A source
The Discussion states that Hsp90 inhibitors in clinical development as anticancer agents are well tolerated in humans. It also reports significant toxicity with two structurally unrelated Hsp90 inhibitors in a mouse model of acute disseminated C. albicans infection. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, in an invertebrate model of fungal pathogenesis, these pharmacological inhibitors of Hsp90 function enhance the efficacy of the two most widely deployed classes of antifungal drugs, azoles and echinocandins, against the two leading fungal pathogens of humans, Candida albicans and Aspergillus fumigatus [22].”
§ Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin > Discussion
What the sources say
- Supportedcites [22] LE Cowen, 2009, Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease., Proc Natl Acad Sci U S A source
The Abstract describes improved efficacy of fluconazole plus Hsp90 inhibitors against C. albicans in Galleria mellonella larvae, and improved larval survival with an Hsp90 inhibitor plus caspofungin against A. fumigatus. The Discussion likewise reports that combination therapy rescued lethal infections with both fungi in this invertebrate host. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This recombinant antibody had therapeutic benefits in a clinical trial in combination with amphotericin B, which targets ergosterol [52].”
§ Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin > Discussion
What the sources say
- Supportedcites [52] J Pachl, 2006, A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis., Clin Infect Dis source
The Abstract identifies Mycograb as a recombinant antibody against fungal heat shock protein 90 and reports better treatment responses when it was combined with lipid-associated amphotericin B than when amphotericin B was given with placebo. The Discussion likewise describes improved clinical and mycological resolution. These passages support the claimed therapeutic benefit in the clinical trial. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with previous findings [23], we confirmed that Hsp90 and calcineurin physically interact in S. cerevisiae (Figure 9A), as they do in C. albicans (Figure 4).”
§ Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin > Results > Divergence of Hsp90 and calcineurin's role in echinocandin tolerance in S. cerevisiae
What the sources say
- Supportedcites [23] J Imai, 2000, Role of HSP90 in salt stress tolerance via stabilization and regulation of calcineurin., Mol Cell Biol source
The Abstract reports that Hsc82, a yeast HSP90 homologue, coimmunoprecipitated with the calcineurin catalytic subunit Cna2 in Saccharomyces cerevisiae cells under normal conditions. The Discussion also says coimmunoprecipitation experiments revealed complexes of Cna2 with Hsp82 and Hsc82, supporting the attributed physical interaction. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
56 more claims · 1 with their cited sources checked
Create a free account to see all 116 claims and every source verdict.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 27
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hsp90 enables crucial responses to drug-induced stress by orchestrating signaling through the protein phosphatase calcineurin and the protein kinase C (PKC) cell wall integrity signaling cascade [41], [46].”
From Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata (2012) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In C. albicans, key client proteins of Hsp90 include the Ca2+-calmodulin-activated protein phosphatase calcineurin, and multiple members of the PKC-MAPK cell wall integrity cascade (Pkc1, Bck1, Mkk2 and Mkc1)75–78.”
From Molecular mechanisms governing antifungal drug resistance (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, Hsp90 inhibition blocks the activation of calcineurin-dependent stress responses and PKC signalling, abrogating tolerance and resistance to the azole and echinocandin drugs76,78.”
From Molecular mechanisms governing antifungal drug resistance (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hsp90 depletion phenocopies the azole sensitivity of calcineurin and protein kinase C mutants96,101.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In Candida albicans and Aspergillus fumigatus, role of Hsp90 in echinocandin resistance has been well established [10].”
From Heat shock protein 90 localizes to the surface and augments virulence factors of Cryptococcus neoformans (2017) · cites this paper as [10]
Experimental — accuracy not yet measured
26 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“and are responsible for a broad spectrum of disease [1,2].”
BackgroundGlobal analysis of protein expression in yeast
Ghaemmaghami, S., Huh, W.-K., Bower, K., Howson, R. W., Belle, A., Dephoure, N., O'Shea, E. K., & Weissman, J. S. (2003) · Nature · doi:10.1038/nature02046 · Cited by 3,750 · cited 1×
“cerevisiae [36].”
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304 · cited 1×
“fumigatus is the principal causal agent of invasive aspergillosis with alarming mortality rates up to 90% that still remain at 40% with the best current treatment options [25,26].”
BackgroundPratt, W. B., & Toft, D. O. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800201 · Cited by 1,483 · cited 1×
“Hsp90 is an essential chaperone that regulates the form and function of many key signal transducers [17–19].”
BackgroundWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444 · cited 1×
“[32,33].”
Structure and mechanism of the Hsp90 molecular chaperone machinery
Pearl, L. H., & Prodromou, C. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142738 · Cited by 1,103 · cited 1×
“Hsp90 is an essential chaperone that regulates the form and function of many key signal transducers [17–19].”
BackgroundRoles of heat-shock proteins in innate and adaptive immunity.
Srivastava, P. (2002) · Nature reviews. Immunology · doi:10.1038/nri749 · Cited by 1,069 · cited 1×
“Consistent with this thinking, heat-shock proteins are immunodominant antigens for the recognition of many pathogens and play a central role in mediating both innate and adaptive immune responses [54,55].”
BackgroundRoe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004 · cited 1×
“[32,33].”
Zhao, R., Davey, M., Hsu, Y.-C., Kaplanek, P., Tong, A., Parsons, A. B., Krogan, N., Cagney, G., Mai, D., Greenblatt, J., et al. (2005) · Cell · doi:10.1016/j.cell.2004.12.024 · Cited by 819 · cited 2×
“cerevisiae [24], while to date not a single Hsp90 client protein has been characterized in C.”
BackgroundZaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005) · Clinical Infectious Diseases · doi:10.1086/496922 · Cited by 784 · cited 1×
“[2,3].”
Cited by
Items 301–364 of 364
da Silva, C. M., de Lima-Neto, R. G., de Carvalho, A. M. R., Macêdo, D. P. C., Melo, A. S. D. A., & Neves, R. P. (2024) · Letters in Applied Microbiology · doi:10.1093/lambio/ovae044 · Cited by 2
Antifungal Resistance in Candida albicans
Seyedjavadi, S. S., Hatami, F., & Jahanshiri, Z. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004578 · Cited by 3
Candida albicans : A Comprehensive View of the Proteome
Gomez-Artiguez, L., Fuentes, S. D. L. C., Sun, Z., Hernáez, M. L., Borrajo, A., Pitarch, A., Molero, G., Monteoliva, L., Moritz, R. L., Deutsch, E. W., et al. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c01020 · Cited by 2
Structural Insights into Selectively Targeting Candida albicans Hsp90
Kowalewski, M. E., Zagler, S. G., & Redinbo, M. R. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00015 · Cited by 2
Fungal Morphogenesis: In Hot Pursuit
Xu, W., & Mitchell, A. P. (2012) · Current Biology · doi:10.1016/j.cub.2012.02.037 · Cited by 2
O’Donnell, L. E., Robertson, D. P., & Ramage, G. (2015) · Springer eBooks · doi:10.1007/978-3-662-47194-4_2 · Cited by 7
Rabies: risk, prognosis and prevention.
Driver, C. (2014) · PubMed · Cited by 3
Rocha, M. C., Santos, C. A., & Malavazi, I. (2018) · Current Proteomics · doi:10.2174/1570164615666180820155807 · Cited by 2
Abrantes, P. M. D. S., Fisher, R., Bouic, P. J., McArthur, C. P., Fielding, B. C., Africa, C. W. J., & Synexa Life Sciences, P. B. 3. (2021) · AIMS Microbiology · doi:10.3934/microbiol.2021020 · Cited by 4
“activity and is implicated in antifungal drug resistance [14,15], iv) Hsp70 proteins SSA1 and SSA2, which affect the fungicidal activity of human antimicrobial peptides [16].”
BackgroundPandey, V., Prasad, M. S. L., & Podile, A. R. (2022) · Physiological and Molecular Plant Pathology · doi:10.1016/j.pmpp.2022.101925 · Cited by 2
Khalili, V., Shokri, H., Khosravi, A., Akim, A. M., & Saroukolaei, S. A. (2016) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2015.12.007 · Cited by 2
Widyana, E. D., Tarsikah, T., & Naimah, N. (2019) · Public Health of Indonesia · doi:10.36685/phi.v5i1.220 · Cited by 2
“Flavonoids, tannins and antioxidant activity found in roses can inhibit the growth of bacteria and fungi (Singh et al., 2009).”
BackgroundA novel Hsp90 phospho-switch modulates virulence in the major human fungal pathogen Candida albicansPreprint
Alaalm, L., Crunden, J. L., Butcher, M. C., Obst, U., Whealy, R. N., Williamson, C. E., O’Brien, H., Schaffitzel, C., Ramage, G., & Diezmann, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.23.309831 · Cited by 2
“Clade 3 (5) T: 5 Dikarya Basidiomycota”
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683670438.mcm0134 · Cited by 2
Yu, J., Jiang, B., Xiong, J., Xu, X., Xu, L., Jiang, Y., & Lu, H. (2026) · Pathogens · doi:10.3390/pathogens15060629 · Cited by 2
“The upc2 ∆ / upc2 ∆ mutant exhibits increased sensitivity to three drugs associated with Ca 2+ homeostasis, including geldanamycin, an Hsp90 inhibitor [37,38], and the calcineurin inhibitors cyclosporine A and tacrolimus [39,40] (Figure 1a).”
Ivanov, M., Stojković, D. S., & Sokóvić, M. (2025) · Springer eBooks · doi:10.1007/978-981-96-1305-2_7 · Cited by 2
Kauser, S., Gulzar, M., Hasan, G. M., & Kumar, P. S. (2025) · Archives of Microbiology · doi:10.1007/s00203-025-04519-5 · Cited by 2
“When Hsp90 is inhibited, calcineurin function is significantly weakened, making C. albicans more sensitive to echinocandin drugs that target the fungal cell wall (Singh et al. 2009).”
Song, J., Cheng, X., Gao, J., Liang, Z., Han, X., & Zhao, H. (2025) · Natural Product Research · doi:10.1080/14786419.2025.2583348 · Cited by 1
He, R., Xie, J., Hao, J., Wang, B., Jin, C., & Fang, W. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.03143-25 · Cited by 1
The effect of microenvironment on Candida albicans morphological switch
Wu, C., Cui, Y., Yang, C., & Tang, J. (2014) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000015 · Cited by 1
“calcineurin [76], tyrosine kinase v-src [77] and MAP kinase Mkc1 [78], which are key regulators of the evolution and maintenance of antifungal drug resistance.”
BackgroundTranscriptome in Human Mycoses
Peres, N. T. A., Persinoti, G. F., Lang, E. A. S., Rossi, A., & Martinez-Rossi, N. M. (2014) · Springer eBooks · doi:10.1007/978-3-319-11985-4_13 · Cited by 4
Diezmann, S., & Cowen, L. E. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1130-1_8 · Cited by 1
“albicans based on the physical interaction between Hsp90 and the catalytic subunit of calcineurin, Cna1, and the destabilization of Cna1 upon depletion of Hsp90 [36].”
BackgroundInfluentialSelf-citationRoy, A., & Tamuli, R. (2022) · Mycological Progress · doi:10.1007/s11557-022-01833-w · Cited by 2
“In C. albicans, Hsps regulate the calcineurin-CRZ-1 pathway via direct interaction of Hsp90 with Cna1; therefore, Hsps serve as a target of antifungal drugs (Singh et al. 2009; Imai and Yahara 2000).”
BackgroundEvolution of Drug Resistance in Fungi
Hill, J. A., Hoot, S. J., White, T. C., & Cowen, L. E. (2012) · Wiley eBooks · doi:10.1002/9781118308165.ch8 · Cited by 1
Self-citationFunctional Genomic and Chemical Biology Analysis of Echinocandin Resistance in Candida albicans
Caplan, T. (2018) · TSpace (University of Toronto) · Cited by 1
Fungi In Asthma - Investigation Of The Lung Mycobiome And Characterisation Of Allergens
Rick, E. (2019) · Figshare · Cited by 1
Roy, A., & Tamuli, R. (2021) · Research Square · doi:10.21203/rs.3.rs-548634/v1 · Cited by 1
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683674849.mcm0134 · Cited by 1
Gifford, H., Pradhan, A., Caswall, B. A., Murphy, S., Leaves, I., Edmondson, M. B., Chakraborty, T., Wilson, D., Taori, S. K., Gow, N. A. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.17.700071 · Cited by 1
Microevolution of Antifungal Drug Resistance
Cowen, L. E. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0667-3_19-1 · Cited by 2
“thereby blocking calcineurin-mediated stress responses required for survival during the stress induced by antifungal drug exposure (Singh et al. 2009).”
BackgroundInfluentialSelf-citationExpressão, regulação e funcionalidade de genes HSPs no dermatófito Trichophyton rubrum
Jacob, T. R. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2016.tde-15052014-105536
albicansated Signaling in Candida Curcumin Targets Cell Wall Integrity via
Singh, A., Sharma, M., Kumar, A., Dhamgaye, S., & Kumar, I. M. K. (2014)
Sun, N. (2013) · DigitalGeorgetown (Georgetown University Library)
Regulation of Fungal Drug Resistance and Morphogenesis by Lysine Deacetylases
Li, X. (2015) · TSpace (University of Toronto)
Shekhar‐Guturja, T. (2016) · TSpace (University of Toronto)
The Roles of Hsp90 and Calcineurin in Antifungal Drug Resistance
Singh, S. (2012) · TSpace (University of Toronto)
Self-citationHill, J. A. (2014) · TSpace (University of Toronto)
Rodríguez-Leguizamón, G. (2016) · Repositorio Institucional E-DocUR (Universidad Del Rosario) · doi:10.48713/10336_13785
Chiaratto, J. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2019.tde-26072019-170555
Targeting Casein Kinases in the Fungal Pathogen Candida albicans
Hyde, S. (2020) · TSpace (University of Toronto)
Germination of a Field: Women in Candida albicans Research
Anderson, F. M., Polvi, E. J., Veri, A. O., & O’Meara, T. R. (2021) · Current Clinical Microbiology Reports · doi:10.1007/s40588-021-00169-5
(2010) · Yeast · doi:10.1002/yea.1714
Perlin, D. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-46718-4_29
Liu, L., Sun, Y., Gao, Z., Yin, W., Jiang, H., Wu, T., Sun, Y., Qin, Q., Zhao, D., & Cheng, M. (2022) · Archiv der Pharmazie · doi:10.1002/ardp.202200266 · Cited by 1
Guo, X., Jiang, J., Qian, L., Xu, J., Che, Z., & Liu, S. (2022) · Research Square · doi:10.21203/rs.3.rs-2157774/v1
Fungal diseases and antifungal drugs
Kumar, A., & Jha, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18744-5.00002-2
Day, A. W., & Kumamoto, C. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.13.557677
“Calculation of the amount of ergosterol and amount of dehydro-661 ergosterol (DHE) normalized to wet pellet weight was performed as described previously [43,82,83].”
Lefranc, M., Accoceberry, I., Biteau, N., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.05.560425
Bende, G., Zsindely, N., Laczi, K., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.14.594093
Isolate Specific Transcriptome Changes Exerted by Isavuconazole Treatment in Candida auris
Balla, N., Kovács, F., Tóth, Z., Harmath, A., Bozó, A., Majoros, L., Kovács, R., & Jakab, Á. (2024) · Mycopathologia · doi:10.1007/s11046-024-00919-1 · Cited by 1
“Singh et al. [51] demonstrated that decreased expression of the HSP90 gene enhanced the sensitivity of C. albicans to azoles and echinocandins and improved the therapeutic efficacy of these drugs in a disseminated C. albicans infection model.”
Vellanki, S., DeMichaelis, N., Liao, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.16.712083
L'interaction Hsp90/co-chaperonnes : nouvelle cible pour le traitement des candidoses invasives
Rouges, C. (2023) · theses.fr (ABES) · doi:10.70675/40b24a3fz159ez4d8ez8a34zdd8ffa1c22fa
Emerging Antifungal Resistance in Ocular Infections
de Oliveira, H. C., Tabuse, A. M., Höfling-Lima, A. L., & Rodrigues, A. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-19923-2_3
Lefranc, M., Accoceberry, I., Fitton‐Ouhabi, V., Biteau, N., & Noël, T. (2026) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlag091
Vellanki, S., DeMichaelis, N., Liao, C., Stajich, J., & Cramer, R. A. (2026) · mBio · doi:10.1128/mbio.00661-26
“S6) affecting the ergosterol pathway, iron starvation, secondary metabolism, oxidative metabolism, cell wall homeostasis, glutathione S-transferases, drug transporters, and heat shock proteins such as Hsp90 that impact antifungal drug efficacy (30, 32, 33, 43, 44) (Fig.”
Micafungin exposure drives multidrug resistance in Clavispora lusitaniaePreprint
Wash, E., Scott, N. E., Metzner, K., Zhou, X., Dasilva, D., de Sá, N. P., Usmani, S. A., Sa, N. F. V. D., Poeta, M. D., & Selmecki, A. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.29.735437
“In C. albicans wild-type cells, Hsp90 inhibition reduces tolerance to MCF and FLC (91, 92).”
Ding, Y., Huang, C., Ning, S., Liu, J., Ge, Y., & Chi, Y. (2026) · Pathogens · doi:10.3390/pathogens15070754
“…phosphoregulatory interactions with client kinases govern morphogenesis, biofilm formation, and echinocandin resistance across Candida species [91–95], and Ptc2-dependent dephosphorylation of Hsp90 within phase-separated condensates directly sensitizes C. albicans to echinocandin treatment [51].”
Parallel evolution under constraint shapes echinocandin resistance in Candida aurisPreprint
Cauldron, N. C., Dort, E. N., Weeks, G., Rogers, P. D., & Cuomo, C. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.30.748140
From confrontation to co-adaptation: the dynamic dialogue of Candida albicans and macrophages
Miramón, P., Wilson, H. B., & Lorenz, M. C. (2026) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00191-22
“Additionally, Hsp90 supports the function of calcineurin and other stress response pathways, ensuring hyphal integrity against membrane perturbations and antifungal challenges (282, 283).”
Mroczyńska, M., Szczepański, P., & Brillowska‐Dąbrowska, A. (2026) · Polish Journal of Veterinary Sciences · doi:10.24425/pjvs.2026.3615
“Resistance mechanisms include modifications of the drug target proteins, overexpression of target enzymes, changes in membrane sterol composition, increased activity of efflux pumps, and activation of cellular stress response pathways (Cannon et al. 2009, Singh et al. 2009).”
Antifungal metallacarboranes modulate Hsp90 activity
Kubiński, K., Czubak, P., Martyna, A., Kozyra, P., Czaplewska, P., Engler, S., Büchner, J., Fink, K., Goszczyński, T., & Masłyk, M. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2732258
“Hsp90 is a particularly promising target for treating C. albicans infections due to its role in stress adaptation [31,69] and morphogenesis [70].”
Yang, F., Sun, L., Li, H., Fang, T., Guo, Q., Chen, N., & Jiang, Y. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1845986
Antifungal Trials: Progress, Approaches, New Targets, and Perspectives in Cryptococcosis
Pappas, P. G. (2014) · ASM Press eBooks · doi:10.1128/9781555816858.ch39
Metadata
- Authors
- Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E.
- Affiliations
- University of Toronto (CA)
- Duke Medical Center (US)
- Corresponding author
- Cowen, Leah E.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-07-31
- Volume
- 5
- Issue
- 7
- Pages
- e1000532
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC2712069
- OpenAlex
- W2087273774
- Cited by
- 362
- References
- 60
- Citations by year
- 2026: 19 · 2025: 26 · 2024: 14 · 2023: 25 · 2022: 24 · 2021: 28 · 2020: 23 · 2019: 18 · 2018: 18 · 2017: 18 · 2016: 20 · 2015: 16 · 2014: 32 · 2013: 25 · 2012: 23
- FWCI
- 12.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Burroughs Wellcome Fund
- University of Toronto
- National Institutes of Health
- Canadian Institutes of Health Research (MOP-86452)
- Natural Sciences and Engineering Research Council of Canada
- National Institute of Allergy and Infectious Diseases (AI 73896, R56AI028388, AI28388, R01AI073896, R01AI028388, K08AI065837)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- HSP90, calcineurin, Candida albicans, echinocandin resistance, antifungal resistance, candidiasis, Hsp90 client proteins, Crz1, calcineurin signaling, molecular chaperones, fungal cell wall biosynthesis, HSP90 inhibition, combination antifungal therapy, systemic candidiasis
- MeSH terms
- Micafungin, Analysis of Variance, Animals, Antifungal Agents, Azoles, Candida albicans, Candidiasis, Disease Models, Animal, DNA-Binding Proteins, Fungal Proteins, Male, Stress, Physiological, Transcription Factors, HSP90 Heat-Shock Proteins, Calcineurin, Drug Resistance, Fungal, Mice, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.